Professor Michael Schneider

Chair in Cardiology
Faculty of Medicine, National Heart & Lung Institute

Professor Michael Schneider's inventions

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity Further information on this technology

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...